MSD and Astellas concluded a co-promotion agreement
OREANDA-NEWS. MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have concluded a co-promotion agreement (“the Agreement”) for a combination drug of the DPP-4 inhibitor sitagliptin phosphate hydrate (brand name: JANUVIA® Tablets) and the SGLT2 inhibitor ipragliflozin L-Proline (brand name: Suglat® Tablets) for the treatment of type-2 diabetes in Japan (MSD has submitted an application for the treatment of type-2 diabetes in Japan). The two companies concluded a basic agreement on co-development and co-commercialization of the drug in Japan in 2015.
MSD will obtain the marketing approval for the drug, and Astellas will distribute it. And MSD and Astellas will jointly provide information to medical institutions according to the Agreement.
JANUVIA® Tablet is the first selective DPP-4 inhibitor in Japan manufactured and marketed by MSD. This once-daily inhibitor selectively inhibits DPP-4 and increases the active incretin levels, thus demonstrating glucose-dependent glucose-lowering effect. Suglat® Tablet is the first selective SGLT2 inhibitor in Japan manufactured and marketed by Astellas. With once-daily administration, it selectively inhibits SGLT2 and blocks renal glucose reuptake, thus demonstrating non-insulin-dependent glucose-lowering effect.